Vulvar and vaginal atrophy in postmenopausal women: Findings from the REVIVE (REal women's VIews of treatment options for menopausal vaginal changEs) survey

Journal of Sexual Medicine

Volumn 10, Issue 7, 2013, Pages 1790-1799

  Kingsberg, Sheryl A ^a   Wysocki, Susan ^b   Magnus, Leslie ^c   Krychman, Michael L ^d,e  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b Obstetric Neonatal Nurses   (United States)

^c SHIONOGI AND CO LTD   (Japan)

^d Southern California Center for Sexual Health and Survivorship Medicine   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dyspareunia; Postmenopausal Women; Sexual Relationships; Survey; Vaginal Dryness; Vulvar and Vaginal Atrophy

Indexed keywords

ESTROGEN; LUBRICATING AGENT; NON PRESCRIPTION DRUG;

ADULT; AGED; ARTICLE; ATROPHY; AWARENESS; DAILY LIFE ACTIVITY; DYSPAREUNIA; ESTROGEN THERAPY; FEMALE; GEOGRAPHIC DISTRIBUTION; HEALTH CARE PERSONNEL; HEALTH STATUS; HEALTH SURVEY; HUMAN; HUMIDIFIER; KNOWLEDGE; MAJOR CLINICAL STUDY; POPULATION DISTRIBUTION; POSTMENOPAUSE; PRESCRIPTION; PRIORITY JOURNAL; SEXUAL BEHAVIOR; SEXUAL FUNCTION; SEXUAL HEALTH; SEXUAL SATISFACTION; UNITED STATES; VAGINA ATROPHY; VAGINA DISCHARGE; VAGINA DISEASE; VAGINA IRRITATION; VAGINAL DRYNESS; VULVA ATROPHY; VULVA DISEASE;

EID: 84879837382     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/jsm.12190     Document Type: Article

References (19)

1. Mac Bride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc 2010;85:87-94.
2. North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause 2007;14(3 Pt 1):355-369.
3. Gass MLS, Cochrane BB, Larson JC, Manson JE, Barnabei VM, Brzyski RG, Lane DS, LaValleur J, Ockene JK, Mouton CP, Barad DH. Patterns and predictors of sexual activity among women in the Hormone Therapy trials of the Women's Health Initiative. Menopause 2011;18:1160-1171.
4. US Census Bureau. Age and Sex Composition: 2010. 2011 May. Report No.: C2010BR-03.
5. Nappi RE, Kokot-Kierepa M. Vaginal Health: Insights, Views & Attitudes (VIVA)-Results from an international survey. Climacteric 2012;15:36-44. [Sponsored by Novo Nordisk].
6. Santoro N, Komi J. Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med 2009;6:2133-2142.
7. Sturdee DW, Panay N. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 2010;13:509-522.
8. Tan O, Bradshaw K, Carr BR. Management of vulvovaginal atrophy-related sexual dysfunction in postmenopausal women: An up-to-date review. Menopause 2012;19:109-117.
9. Shulman LP, Portman DJ, Lee WC, Balu S, Joshi AV, Cobden D, Wang Q, Pashos CL. A retrospective managed care claims data analysis of medication adherence to vaginal estrogen therapy: Implications for clinical practice. J Womens Health (Larchmt) 2008;17:569-578.
10. Wyeth. REVEAL: REvealing Vaginal Effects At mid-Life. Surveys of Postmenopausal Women and Health Care Professionals Who Treat Postmenopausal Women. 2009. [Sponsored by Pfizer Pharmaceuticals].
11. Pfizer Pharmaceuticals, Inc. Healthy women survey. Available at: http://www.personalmenopauseanswers.com/healthy-%20women-survey.aspx (accessed August 11, 2012). [Sponsored by Pfizer Pharmaceuticals].
12. Novo Nordisk. Data reveal the negative emotional and physical impact that a silent symptom of menopause has on U.S. women and their partners. Press release; October 5, 2012. [Sponsored by Novo Nordisk].
13. Sutton KS, Boyer SC, Goldfinger C, Ezer P, Pukall CF. To lube or not to lube: Experiences and perceptions of lubricant use in women with and without dyspareunia. J Sex Med 2012;9:240-250.
14. North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010;17:242-255.
15. Lake Research Partners. New Survey: Majority of Women Suffering Menopausal Symptoms Are Not Receiving Treatment; Many Not Talking to Doctors about Treatment Options. 2012.
16. ® (estradiol vaginal tablets) [prescribing information]. Novo Nordisk Inc, Princeton, NJ. Date of issue: April 2012.
17. ® (estradiol vaginal cream) [prescribing information]. Warner Chilcott (US), LLC, Rockaway, NJ. Revised July 2011.
18. Krychman ML. Vaginal estrogens for the treatment of dyspareunia. J Sex Med 2011;8:666-674.
19. Carter J, Goldfrank D, Schover LR. Simple strategies for vaginal health promotion in cancer survivors. J Sex Med 2011;8:549-559.